Zumutor Biologics
Biologics company focused on discovery and development of NK cell–directed immunotherapies and engineered monoclonal antibodies. Operates an antibody‑discovery platform using high‑diversity human libraries and combined phage/yeast display, maintains R&D facilities in India and a corporate presence in Massachusetts, and advances lead candidates through CMC, GLP toxicology and early clinical development.
Industries
Nr. of Employees
small (1-50)
Zumutor Biologics
Patents
Vectors for cloning and expression of proteins, methods and applications thereof
US-11549119-B2
View DetailsDNA-binding domain of CRISPR system, non-fucosylated and partially fucosylated proteins, and methods thereof
US-11548937-B2
View DetailsMethod of generating an antibody naïve library, said library and application(s) thereof
US-11384354-B2
View Details
Vectors for cloning and expression of proteins, methods and applications thereof
US-11549119-B2
View DetailsDNA-binding domain of CRISPR system, non-fucosylated and partially fucosylated proteins, and methods thereof
US-11548937-B2
View DetailsMethod of generating an antibody naïve library, said library and application(s) thereof
US-11384354-B2
View DetailsProducts
ZM008 (anti‑LLT1 monoclonal antibody)
A first‑in‑class fully human IgG1 monoclonal antibody that blocks the LLT1–CD161 interaction to activate NK cell cytotoxicity and modulate tumor microenvironment; supported by in‑vitro, in‑vivo efficacy and non‑clinical safety studies. Advanced into a first‑in‑human Phase I trial (NCT06451497).
ZM012 (monoclonal antibody candidate)
Preclinical antibody program targeting a tumor‑associated antigen engaging NK cell receptors; lead clone identification in progress and planned animal efficacy studies.
ZM014 (monoclonal antibody candidate)
Preclinical antibody program directed at NK cell receptor biology; candidate identification and preclinical efficacy testing planned.
ZM008
ZM008 is a first-in-class fully human IgG1 monoclonal antibody targeting LLT1, a novel innate immune checkpoint designed for the treatment of solid tumors.
ZM008 Anti-LLT1 mAb
Potential first-in-class antibody targeting LLT1-Lectin Like Transcript 1 focused on indications such as Prostate Cancer, B cell lymphoma, Glioblastoma, and Rheumatoid Arthritis.
ZM012 mAb
Monoclonal antibody candidate functioning through tumour associated antigen/NK cell receptor for lymphoma and other undisclosed indications.
ZM008 (anti‑LLT1 monoclonal antibody)
A first‑in‑class fully human IgG1 monoclonal antibody that blocks the LLT1–CD161 interaction to activate NK cell cytotoxicity and modulate tumor microenvironment; supported by in‑vitro, in‑vivo efficacy and non‑clinical safety studies. Advanced into a first‑in‑human Phase I trial (NCT06451497).
ZM012 (monoclonal antibody candidate)
Preclinical antibody program targeting a tumor‑associated antigen engaging NK cell receptors; lead clone identification in progress and planned animal efficacy studies.
ZM014 (monoclonal antibody candidate)
Preclinical antibody program directed at NK cell receptor biology; candidate identification and preclinical efficacy testing planned.
ZM008
ZM008 is a first-in-class fully human IgG1 monoclonal antibody targeting LLT1, a novel innate immune checkpoint designed for the treatment of solid tumors.
ZM008 Anti-LLT1 mAb
Potential first-in-class antibody targeting LLT1-Lectin Like Transcript 1 focused on indications such as Prostate Cancer, B cell lymphoma, Glioblastoma, and Rheumatoid Arthritis.
ZM012 mAb
Monoclonal antibody candidate functioning through tumour associated antigen/NK cell receptor for lymphoma and other undisclosed indications.
Services
Discovery from high‑diversity human libraries using combined phage and yeast display, screening in Fab/ScFv formats, novelty confirmation and transfer to mammalian expression for development.
Flexible full‑service vertical for analytical method development, process development and intermediate‑scale DS manufacturing support.
Discovery from high‑diversity human libraries using combined phage and yeast display, screening in Fab/ScFv formats, novelty confirmation and transfer to mammalian expression for development.
Flexible full‑service vertical for analytical method development, process development and intermediate‑scale DS manufacturing support.
Expertise Areas
- Antibody discovery and engineering
- NK cell–directed immunotherapy
- Preclinical pharmacology and toxicology
- CMC and biologics process development
Key Technologies
- Phage display
- Yeast surface display
- High‑diversity human antibody libraries (naïve, synthetic, semi‑synthetic)
- Fab and ScFv screening
News & Updates
Regulatory clearance of an IND application for the lead anti‑LLT1 antibody enabling clinical development.
First‑in‑human Phase I study patient dosed in the United States for the anti‑LLT1 antibody program.
Notice of allowance from the USPTO for the lead antibody composition.
Reported completion of GLP toxicology studies, pharm/tox with PK/PD data, in‑vivo efficacy and downstream manufacturing steps at 250 L scale supporting IND readiness.
Publication and analyses describing LLT1 as a target and therapeutic rationale for anti‑LLT1 antibodies in multiple solid tumors.
Method paper on explainable ML applied to TIGIT‑linked gene signatures for clinical outcome biomarkers.
Regulatory clearance of an IND application for the lead anti‑LLT1 antibody enabling clinical development.
First‑in‑human Phase I study patient dosed in the United States for the anti‑LLT1 antibody program.
Notice of allowance from the USPTO for the lead antibody composition.
Reported completion of GLP toxicology studies, pharm/tox with PK/PD data, in‑vivo efficacy and downstream manufacturing steps at 250 L scale supporting IND readiness.
Publication and analyses describing LLT1 as a target and therapeutic rationale for anti‑LLT1 antibodies in multiple solid tumors.
Method paper on explainable ML applied to TIGIT‑linked gene signatures for clinical outcome biomarkers.